Account-based marketing best practices for 2026 for healthcare and life sciences in Southern Europe
The current, revised best practices for account-based marketing — updated for what actually works in the buyer environment of 2026. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Southern Europe.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Southern Europe. In this market, Southern European buyers reward relationship depth over transactional outreach, so the way you install account-based marketing has to be shaped to that reality from day one.
Best practices for account-based marketing have shifted. The 2022 playbook does not survive the current buyer environment. This is the update.
Best practice one: fewer accounts, sharper triggers. One enterprise close is worth six mid-market ones, and generic coverage is now negative signal.
Best practice two: publish pipeline created inside the named-account list weekly. If leadership does not see the number, the model quietly drifts.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Southern Europe it is compounded by the fact that relationship depth, not activity volume is what actually gates growth. Account-based marketing is only useful here when it is pointed at both constraints at once.
Best practice three: separate the sending infrastructure from the primary brand. Deliverability is a strategic asset.
Best practice four: name a single owner. Committees produce compromise; owners produce numbers.
Best practice five: pre-write kill criteria. A stated failure threshold is what prevents the sunk-cost trap.
Best practice six: run monthly retrospectives that are honest about what did not work. Account-based marketing improves faster on failure data than on success data.
Concretely for healthcare and life sciences in Southern Europe: the healthcare teams that install this get past procurement instead of dying in it, and a single trusted Southern European relationship compounds into a regional beachhead. That is the reason it is worth installing account-based marketing deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
ABM · healthcare · Southern Europe — answered
- Does account-based marketing work for healthcare and life sciences in Southern Europe?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Southern Europe, Southern European buyers reward relationship depth over transactional outreach. The healthcare teams that install this get past procurement instead of dying in it.
- What changed in account-based marketing best practices for 2026?
- Buyers are less tolerant of generic coverage; specificity and trigger quality now dominate.
- Which best practice is most under-implemented?
- Pre-written kill criteria. Almost no team has them; every team benefits from them.
- Do best practices change by company size?
- Governance scales with size; core principles remain identical.
- How do I know a best practice is working?
- Pipeline created inside the named-account list improves, and improvements survive a month.
- What is the Southern Europe-specific pitfall when running account-based marketing for healthcare?
- Importing a playbook that was built for another market. In Southern Europe, Southern European buyers reward relationship depth over transactional outreach — the install has to reflect that.
Growth Broker editorial
Filed under abm · healthcare · southern europe